U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06905262) titled 'Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)' on March 25.
Brief Summary: Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: From Benchside to Bedside (HepAnt) - Study of the Role of the Metagenome in Head and Neck Tumors Using Omics Techniques (HeNomics).
Study Start Date: Jan. 02, 2023
Study Type: OBSERVATIONAL
Condition:
Hepatocellular Carcinoma
Recruitment Status: RECRUITING
Sponsor: National Cancer Institute, Naples
Published by HT Digital Content Services with permission from Health Daily Digest....